The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-4329
+8 800 250-18-12
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Asaulenko Z.P.

St. Petersburg City Hospital No 40

Spiridonov I.N.

St. Petersburg City Hospital No 40

Baram D.V.

Russian Research Institute of Hematology and Transfusiology

Krivolapov Yu.A.

North-Western State Medical University named after I.I. Mechnikov

WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2022 (5th edition): Myeloid and Histiocytic Tumors

Authors:

Asaulenko Z.P., Spiridonov I.N., Baram D.V., Krivolapov Yu.A.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2023;85(5): 36‑44

DOI: 10.17116/patol20238505136

Read: 8298 times

Download PDF (RU)
Contact the author
Table of contents

WHO CLASSIFICATION OF TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES, 2022 (5TH EDITION): MYELOID AND HISTIOCYTIC TUMORS
WHO CLASSIFICATION OF TUMORS OF HEMATOPOIETIC AND LYMPHOID TISSUES, 2022 (5TH EDITION): MYELOID AND HISTIOCYTIC TUMORS

To cite this article:

Asaulenko ZP, Spiridonov IN, Baram DV, Krivolapov YuA. WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues, 2022 (5th edition): Myeloid and Histiocytic Tumors. Russian Journal of Archive of Pathology. 2023;85(5):36‑44. (In Russ.)
https://doi.org/10.17116/patol20238505136

Подписка 2026 Архив патологии (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Использование инфографики авторами научных работ
Close metadata
Recommended articles:
Endo­thelial factors for prediction of mortality in blood cancer patients with sepsis. Russian Journal of Anesthesiology and Reanimatology. 2025;(5):74-80
Abstract:

The article reviews the changes in the structure of classification, diagnostic criteria for myeloid and histiocytic neoplasms in the 5th edition of the WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues (2022). Information is presented regarding new nosological forms, renaming and abolition of some previously existing ones. The importance of molecular genetic studies in the isolation of myeloid and histiocytic neoplasms and the need to apply these studies in clinical practice are emphasized. Myeloid and histiocytic precancerous and proliferative processes, genetic tumor syndromes, introduced into the classification for the first time, are considered.

Keywords:

classification of myeloid and histiocytic tumors
leukemia
histiocytic neoplasm
plasmacytoid dendritic cell neoplasm
myeloid proliferations
clonal haematopoiesis

Authors:

Asaulenko Z.P.

St. Petersburg City Hospital No 40

Spiridonov I.N.

St. Petersburg City Hospital No 40

Baram D.V.

Russian Research Institute of Hematology and Transfusiology

Krivolapov Yu.A.

North-Western State Medical University named after I.I. Mechnikov

Received:

06.06.2023

Accepted:

21.06.2023

Close metadata

References:

  1. WHO Classification of Tumours Online. Haematolymphoid tumours. Beta version ahead of print. 5th ed. France, Lyon: International Agency for Research on Cancer; 2022. https://tumourclassification.iarc.who.int/chapters/63
  2. Buscarlet M, Provost S, Zada YF, Barhdadi A, Bourgoin V, Lé pine G, Mollica L, Szuber N, Dubé MP, Busque L. DNMT3A and TET2 dominate clonal hematopoiesis and demonstrate benign phenotypes and different genetic predispositions. Blood. 2017;130(6): 753-762.  https://doi.org/10.1182/blood-2017-04-777029
  3. Steensma DP, Bejar R, Jaiswal S, Lindsley RC, Sekeres MA, Hasserjian RP, Ebert BL. Clonal hematopoiesis of indeterminate potential and its distinction from myelodysplastic syndromes. Blood. 2015;126(1):9-16.  https://doi.org/10.1182/blood-2015-03-631747
  4. Easwar A, Siddon AJ. Genetic landscape of myeloproliferative neoplasms with an emphasis on molecular diagnostic laboratory testing. Life (Basel). 2021;11(11):1158. https://doi.org/10.3390/life11111158
  5. Loscocco GG, Guglielmelli P, Vannucchi AM. Impact of mutational profile on the management of myeloproliferative neoplasms: a short review of the emerging data. Onco Targets Ther. 2020;13:12367-12382. https://doi.org/10.2147/ott.s287944
  6. Fang H, Ketterling RP, Hanson CA, Pardanani A, Kurtin PJ, Chen D, Greipp PT, Howard MT, King RL, Van Dyke DL, et al. A test utilization approach to the diagnostic workup of isolated eosinophilia in otherwise morphologically unremarkable bone marrow: a single institutional experience. Am J Clin Pathol. 2018; 150(5):421-431.  https://doi.org/10.1093/ajcp/aqy064
  7. Deschamps P, Moonim M, Radia D, Curto-Garcia N, Woodley C, Bassiony S, O’Sullivan J, Harrington P, Raj K, Francis Y, et al. Clinicopathological characterisation of myeloproliferative neoplasm-unclassifiable (MPN-U): a retrospective analysis from a large UK tertiary referral centre. Br J Haematol. 2021;193(4):792-797.  https://doi.org/10.1111/bjh.17375
  8. Gupta AK, Meena JP, Chopra A, Tanwar P, Seth R. Juvenile myelomonocytic leukemia — a comprehensive review and recent advances in management. Am J Blood Res. 2021;11(1):1-21. 
  9. Valent P, Akin C, Hartmann K, Alvarez-Twose I, Brockow K, Hermine O, Niedoszytko M, Schwaab J, Lyons JJ, Carter MC, et al. Updated diagnostic criteria and classification of mast cell disorders: a consensus proposal. Hemasphere. 2021;5(11):e646. https://doi.org/10.1097/hs9.0000000000000646
  10. Malcovati L, Stevenson K, Papaemmanuil E, Neuberg D, Bejar R, Boultwood J, Bowen DT, Campbell PJ, Ebert BL, Fenaux P, et al. SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS. Blood. 2020;136(2):157-170.  https://doi.org/10.1182/blood.2020004850
  11. Pastor V, Hirabayashi S, Karow A, Wehrle J, Kozyra EJ, Nienhold R, Ruzaike G, Lebrecht D, Yoshimi A, Niewisch M, et al. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants. Leukemia. 2017;31(3):759-762.  https://doi.org/10.1038/leu.2016.342
  12. Baumann I, Führer M, Behrendt S, Campr V, Csomor J, Furlan I, de Haas V, Kerndrup G, Leguit RJ, De Paepe P, et al. Morphological differentiation of severe aplastic anaemia from hypocellular refractory cytopenia of childhood: reproducibility of histopathological diagnostic criteria. Histopathology. 2012;61(1):10-17.  https://doi.org/10.1111/j.1365-2559.2011.04156.x
  13. Sahoo SS, Kozyra EJ, Wlodarski MW. Germline predisposition in myeloid neoplasms: unique genetic and clinical features of GATA2 deficiency and SAMD9/SAMD9L syndromes. Best Pract Res Clin Haematol. 2020;33(3):101197. https://doi.org/10.1016/j.beha.2020.101197
  14. Calvo X, Garcia-Gisbert N, Parraga I, Gibert J, Florensa L, Andrade-Campos M, Merchan B, Garcia-Avila S, Montesdeoca S, Fernández-Rodríguez C, et al. Oligomonocytic and overt chronic myelomonocytic leukemia show similar clinical, genomic, and immunophenotypic features. Blood Adv. 2020;4(20):5285-5296. https://doi.org/10.1182/bloodadvances.2020002206
  15. Patnaik MM, Timm MM, Vallapureddy R, Lasho TL, Ketterling RP, Gangat N, Shi M, Tefferi A, Solary E, Reichard KK, et al. Flow cytometry based monocyte subset analysis accurately distinguishes chronic myelomonocytic leukemia from myeloproliferative neoplasms with associated monocytosis. Blood Cancer J. 2017;7(7):e584. https://doi.org/10.1038/bcj.2017.66
  16. Loghavi S, Sui D, Wei P, Garcia-Manero G, Pierce S, Routbort MJ, Jabbour EJ, Pemmaraju N, Kanagal-Shamanna R, Gur HD, et al. Validation of the 2017 revision of the WHO chronic myelomonocytic leukemia categories. Blood Adv. 2018;2(15):1807-1816. https://doi.org/10.1182/bloodadvances.2018019224
  17. Quintana-Bustamante O, Lan-Lan Smith S, Griessinger E, Reyal Y, Vargaftig J, Lister TA, Fitzgibbon J, Bonnet D. Overexpression of wild-type or mutants forms of CEBPA alter normal human hematopoiesis. Leukemia. 2012;26(7):1537-1546. https://doi.org/10.1038/leu.2012.38
  18. Gao Y, Jia M, Mao Y, Cai H, Jiang X, Cao X, Zhou D, Li J. Distinct mutation landscapes between acute myeloid leukemia with myelodysplasia-related changes and de novo acute myeloid leukemia. Am J Clin Pathol. 2022;157(5):691-700.  https://doi.org/10.1093/ajcp/aqab172
  19. Engel NW, Reinert J, Borchert NM, Panagiota V, Gabdoulline R, Thol F, Heuser M, Fiedler W. Newly diagnosed isolated myeloid sarcoma-paired NGS panel analysis of extramedullary tumor and bone marrow. Ann Hematol. 2021;100(2):499-503.  https://doi.org/10.1007/s00277-020-04313-x
  20. Kuendgen A, Nomdedeu M, Tuechler H, Garcia-Manero G, Komrokji RS, Sekeres MA, Della Porta MG, Cazzola M, DeZern AE, Roboz GJ, et al. Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification — an approach to classification of patients with t-MDS. Leukemia. 2021;35(3):835-849.  https://doi.org/10.1038/s41375-020-0917-7
  21. Gao J, Chen Y, Sukhanova M. Molecular pathogenesis in myeloid neoplasms with germline predisposition. Life (Basel). 2021;12(1):46.  https://doi.org/10.3390/life12010046
  22. Schwaab J, Naumann N, Luebke J, Jawhar M, Somervaille TCP, Williams MS, Frewin R, Jost PJ, Lichtenegger FS, La Rosée P, et al. Response to tyrosine kinase inhibitors in myeloid neoplasms associated with PCM1-JAK2, BCR-JAK2 and ETV6-ABL1 fusion genes. Am J Hematol. 2020;95(7):824-833.  https://doi.org/10.1002/ajh.25825
  23. Alexander TB, Gu Z, Iacobucci I, Dickerson K, Choi JK, Xu B, Payne-Turner D, Yoshihara H, Loh ML, Horan J, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. Nature. 2018;562(7727):373-379.  https://doi.org/10.1038/s41586-018-0436-0
  24. Guy J, Antony-Debré I, Benayoun E, Arnoux I, Fossat C, Le Garff-Tavernier M, Raimbault A, Imbert M, Maynadié M, Lacombe F, et al.; GEIL (Groupe d’Etude Immunologique des Leucémies). Flow cytometry thresholds of myeloperoxidase detection to discriminate between acute lymphoblastic or myeloblastic leukaemia. Br J Haematol. 2013;161(4):551-555.  https://doi.org/10.1111/bjh.12277
  25. Lucas N, Duchmann M, Rameau P, Noël F, Michea P, Saada V, Kosmider O, Pierron G, Fernandez-Zapico ME, Howard MT, et al. Biology and prognostic impact of clonal plasmacytoid dendritic cells in chronic myelomonocytic leukemia. Leukemia. 2019;33(10):2466-2480. https://doi.org/10.1038/s41375-019-0447-3
  26. Kemps PG, Picarsic J, Durham BH, Hélias-Rodzewicz Z, Hiemcke-Jiwa L, van den Bos C, van de Wetering MD, van Noesel CJM, van Laar JAM, Verdijk RM, et al. ALK-positive histiocytosis: a new clinicopathologic spectrum highlighting neurologic involvement and responses to ALK inhibition. Blood. 2022;139(2):256-280.  https://doi.org/10.1182/blood.2021013338
  27. Jacobsen E, Shanmugam V, Jagannathan J. Rosai-Dorfman disease with activating KRAS mutation — response to cobimetinib. N Engl J Med. 2017;377(24):2398-2399. https://doi.org/10.1056/NEJMc1713676
  28. Egan C, Lack J, Skarshaug S, Pham TA, Abdullaev Z, Xi L, Pack S, Pittaluga S, Jaffe ES, Raffeld M. The mutational landscape of histiocytic sarcoma associated with lymphoid malignancy. Mod Pathol. 2021;34(2):336-347.  https://doi.org/10.1038/s41379-020-00673-x
  29. Behrens YL, Göhring G, Bawadi R, Cöktü S, Reimer C, Hoffmann B, Sänger B, Käfer S, Thol F, Erlacher M, et al. A novel classification of hematologic conditions in patients with Fanconi anemia. Haematologica. 2021;106(11):3000-3003. https://doi.org/10.3324/haematol.2021.279332
  30. Stieglitz E, Taylor-Weiner AN, Chang TY, Gelston LC, Wang YD, Mazor T, Esquivel E, Yu A, Seepo S, Olsen S, et al. The genomic landscape of juvenile myelomonocytic leukemia. Nat Genet. 2015;47(11):1326-1333. https://doi.org/10.1038/ng.3400
Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register

We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.